470 related articles for article (PubMed ID: 17335902)
1. Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice.
Ghaemi A; Soleimanjahi H; Bamdad T; Soudi S; Arefeian E; Hashemi SM; Ebtekar M
Comp Immunol Microbiol Infect Dis; 2007 Jul; 30(4):197-210. PubMed ID: 17335902
[TBL] [Abstract][Full Text] [Related]
2. Coexpression of interleukin-2 enhances the immunization effect of a DNA vaccine expressing herpes simplex 1 glycoprotein D.
Li WR; Niu B; Wang JW; Feng ZJ; Wang DX
Acta Virol; 2006; 50(4):251-6. PubMed ID: 17177610
[TBL] [Abstract][Full Text] [Related]
3. DNA vaccine-encoded glycoprotein B of HSV-1 fails to protect chronic morphine-treated mice against HSV-1 challenge.
Jamali A; Roostaee MH; Soleimanjahi H; Ghaderi Pakdel F; Bamdad T
Comp Immunol Microbiol Infect Dis; 2007 Mar; 30(2):71-80. PubMed ID: 17126902
[TBL] [Abstract][Full Text] [Related]
4. Preventive effect of local plasmid DNA vaccine encoding gD or gD-IL-2 on herpetic keratitis.
Inoue T; Inoue Y; Nakamura T; Yoshida A; Takahashi K; Inoue Y; Shimomura Y; Tano Y; Fujisawa Y; Aono A; Hayashi K
Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4209-15. PubMed ID: 11095617
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of a DNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D in decreasing ocular disease severity following corneal HSV-1 challenge.
Frye TD; Chiou HC; Hull BE; Bigley NJ
Arch Virol; 2002 Sep; 147(9):1747-59. PubMed ID: 12209314
[TBL] [Abstract][Full Text] [Related]
6. Intravascular naked DNA vaccine encoding glycoprotein B induces protective humoral and cellular immunity against herpes simplex virus type 1 infection in mice.
Cui FD; Asada H; Kishida T; Itokawa Y; Nakaya T; Ueda Y; Yamagishi H; Gojo S; Kita M; Imanishi J; Mazda O
Gene Ther; 2003 Dec; 10(25):2059-66. PubMed ID: 14595378
[TBL] [Abstract][Full Text] [Related]
7. Innate and acquired immunity to herpes simplex virus type 1.
Halford WP; Veress LA; Gebhardt BM; Carr DJ
Virology; 1997 Sep; 236(2):328-37. PubMed ID: 9325240
[TBL] [Abstract][Full Text] [Related]
8. Establishment of latent herpes simplex virus type 1 infection in resistant, sensitive, and immunodeficient mouse strains.
Ellison AR; Yang L; Voytek C; Margolis TP
Virology; 2000 Mar; 268(1):17-28. PubMed ID: 10683323
[TBL] [Abstract][Full Text] [Related]
9. [A kinetic study of gamma interferon production in herpes simplex virus-1 DNA prime-protein boost regimen comparing to DNA or subunit vaccination].
Arefian E; Bamdad T; Soleimanjahi H; Akhood MR; Parsania M; Ghaemi A
Mol Biol (Mosk); 2009; 43(3):422-8. PubMed ID: 19548528
[TBL] [Abstract][Full Text] [Related]
10. [Enhancement of herpes simplex virus-1 glycoprotein-D DNA vaccine induced specific immune responses by coimmunization with interleukin-2 genetic adjuvant].
Liu XJ; Zhu MZ; Song GX; Xu YF; Liu HW; Wang S; Yang BL; Dong FT; Xu XM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Feb; 27(1):67-72. PubMed ID: 15782496
[TBL] [Abstract][Full Text] [Related]
11. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine.
Jamali A; Mahdavi M; Hassan ZM; Sabahi F; Farsani MJ; Bamdad T; Soleimanjahi H; Motazakker M; Shahabi S
Int Immunol; 2009 Mar; 21(3):217-25. PubMed ID: 19174474
[TBL] [Abstract][Full Text] [Related]
12. Herpes Simplex Virus 1 (HSV-1) 0ΔNLS Live-Attenuated Vaccine Protects against Ocular HSV-1 Infection in the Absence of Neutralizing Antibody in HSV-1 gB T Cell Receptor-Specific Transgenic Mice.
Gmyrek GB; Filiberti A; Montgomery M; Chitrakar A; Royer DJ; Carr DJJ
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999018
[TBL] [Abstract][Full Text] [Related]
13. Herpes simplex virus type 1 envelope subunit vaccine not only protects against lethal virus challenge, but also may restrict latency and virus reactivation.
Rajcáni J; Sabó A; Mucha V; Kostál M; Compel P
Acta Virol; 1995 Feb; 39(1):37-49. PubMed ID: 7572468
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of DNA encoding IFN-alpha1 against corneal HSV-1 infection.
Noisakran SJ; Carr DJ
Curr Eye Res; 2000 May; 20(5):405-12. PubMed ID: 10855035
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-12- and gamma interferon-dependent innate immunity are essential and sufficient for long-term survival of passively immunized mice infected with herpes simplex virus type 1.
Vollstedt S; Franchini M; Alber G; Ackermann M; Suter M
J Virol; 2001 Oct; 75(20):9596-600. PubMed ID: 11559791
[TBL] [Abstract][Full Text] [Related]
16. Neuroinvasive properties of herpes simplex virus type 1 glycoprotein variants are controlled by the immune response.
Mitchell BM; Stevens JG
J Immunol; 1996 Jan; 156(1):246-55. PubMed ID: 8598469
[TBL] [Abstract][Full Text] [Related]
17. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
[TBL] [Abstract][Full Text] [Related]
18. An M2 Rather than a T
Lee DH; Ghiasi H
J Virol; 2018 May; 92(10):. PubMed ID: 29491152
[TBL] [Abstract][Full Text] [Related]
19. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone.
Meseda CA; Elkins KL; Merchlinsky MJ; Weir JP
J Infect Dis; 2002 Oct; 186(8):1065-73. PubMed ID: 12355355
[TBL] [Abstract][Full Text] [Related]
20. Persistent cytokine expression in trigeminal ganglion latently infected with herpes simplex virus type 1.
Halford WP; Gebhardt BM; Carr DJ
J Immunol; 1996 Oct; 157(8):3542-9. PubMed ID: 8871654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
